InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China#InnoCare #Announces #Approval #Clinical #Trial #BCL2 #Inhibitor #Mesutoclax #Myelodysplastic #Syndromes #China